Establishment Labs Holdings, Inc. (ESTA)

Establishment Labs Holdings, Inc. stock has experienced a 49.35% rise from November 25, 2024, to November 27, 2025, with a 52-week range of $26.55 to $72.33. The announcement of third-quarter 2025 financial results, exceeding expectations with an EPS of -$0.38 and revenue of $53.8 million, led to an 8.3% pre-market increase. The company presented at the Jefferies London Healthcare Conference on November 7, 2025. Analyst ratings have also influenced the stock, with Mizuho increasing its target price and Canaccord Genuity Group initiating coverage with a "buy" rating.

Demand for Establishment Labs' products exhibits seasonality, with the third quarter typically being slower for breast procedures. The fourth quarter is generally the strongest. Despite the seasonal slowdown, Establishment Labs reported a 16% sequential increase in U.S. sales during Q3 2025 and anticipates acceleration in its U.S. and international businesses in the fourth quarter.

Establishment Labs Holdings, Inc. specializes in aesthetic and reconstructive plastic surgery products, focusing on women's health and wellness. The company designs, develops, manufactures, and markets silicone-filled breast and body-shaping implants under the Motiva brand. They also offer the Motiva Flora Tissue Expander, Mia Femtech, and distribute the Puregraft line of products. Products are distributed through direct sales to medical distributors, physicians, hospitals, and clinics.

Establishment Labs has a global presence with products approved for sale in over 80 countries. Its geographical segments include Europe, Latin America, Asia-Pacific/Middle East, Africa, and North America. Manufacturing is primarily conducted at two facilities in Costa Rica. The company maintains subsidiaries in the United States, Belgium, Brazil, France, Sweden, and Switzerland.

Establishment Labs has maintained a positive brand reputation through its focus on patient safety, customization, and innovation. Motiva Implants are recognized for advanced safety features and superior design, with clinical data showing low complication rates. The publication of the Mia Femtech 3-Year Prospective Study Results and the 2025 Post-Market Surveillance Report have positively affected the company's reputation. Achieving its first quarter of positive Adjusted EBITDA in Q3 2025 has also bolstered its standing.

Establishment Labs Holdings, Inc. is primarily owned by institutional investors, holding approximately 67.76% to 79.72% of the stock. Insiders own about 19.92%, while public companies and individual/retail investors hold approximately 0.36% to 0.91%. Major institutional shareholders include JW Asset Management, LLC, Rtw Investments, Lp, and Brown Advisory Inc, with JW Asset Management, LLC owning the most shares.